Table 2.
Seroprevalence (SeroP, in percentage), median concentration and the respective IQR per study group and herpesvirus IgG antibody, where P-value refers to the Pearson’s χ2 test for seroprevalence-based analysis and the Kruskal-Wallis test for the corresponding quantitative data.
| Herpesvirus (Antigen) | Analysis | ME/CFS_S0 | ME/CFS_S1 | ME/CFS_S2 | ME/CFS_S3 | MS | P-value |
|---|---|---|---|---|---|---|---|
| CMV | SeroP (95% CI) | 42.9 (27.7; 59.0) | 25.6 (13.5; 41.2) | 37.0 (27.1; 47.7) | 18.8 (8.9; 32.6) | 45.0 (29.3; 61.5) | 0.035 |
| Median (IQR) | 5.4 (78.5) | 4.6 (13.3) | 6 (59.8) | 5.4 (1.5) | 5.8 (64.4) | 0.407 | |
| EBV (EBNA1) | SeroP (95% CI) | 71.4 (55.4; 84.3) | 58.1 (42.1; 73.0) | 75.0 (64.9; 83.4) | 75.0 (60.4; 86.4) | 95.0 (83.1; 99.4) | 0.004 |
| Median (IQR) | 39.3 (17.8) | 24.6 (17.1) | 37.2 (23.5) | 32.9 (26.4) | 46.9 (17.8) | 0.006 | |
| EBV (VCA) | SeroP (95% CI) | 88.1 (74.4; 96.0) | 74.4 (58.8; 86.5) | 84.8 (75.8; 91.4) | 95.8 (85.7; 99.5) | 92.5 (79.6; 98.4) | 0.030 |
| Median (IQR) | 99.4 (64.4) | 88.0 (64.8) | 108.9 (49.9) | 129.5 (48.6) | 155.4 (33.8) | 0.003 | |
| HHV6 | SeroP (95% CI) | 85.7 (71.5; 94.6) | 90.7 (77.9; 97.4) | 92.4 (84.9; 96.9) | 100.0 (92.6; 100.0) | 90.0 (76.3; 97.2) | 0.146 |
| Median (IQR) | 38.3 (21.1) | 42.5 (24.3) | 47.5 (25.2) | 43.0 (29.7) | 43.4 (50.8) | 0.418 | |
| HSV1 | SeroP (95% CI) | 50.0 (34.2; 65.8) | 34.9 (21.0; 50.9) | 43.5 (33.2; 54.2) | 54.2 (39.2; 68.6) | 57.5 (40.9; 73.0) | 0.207 |
| Median (IQR) | 12.1 (89.5) | 6.6 (56.5) | 7.6 (108.8) | 16.5 (119.7) | 22.6 (109.6) | 0.273 | |
| HSV2 | SeroP (95% CI) | 50.0 (34.2; 65.8) | 30.2 (17.2; 46.6) | 35.9 (26.1; 46.5) | 45.8 (31.4; 60.8) | 40.0 (24.9; 56.7) | 0.309 |
| Median (IQR) | 12.2 (61.4) | 5.0 (33.5) | 4.1 (45.0) | 6.2 (41.8) | 8.1 (41.8) | 0.650 | |
| VZV | SeroP (95% CI) | 95.2 (83.8; 99.4) | 93.0 (80.9; 98.5) | 100.0 (96.1; 100.0) | 97.9 (88.9; 99.9) | 97.5 (86.8; 99.9) | 0.169 |
| Median (IQR) | 129.5 (46.2) | 119.7 (20.8) | 135.7 (48.4) | 142.2 (35.8) | 156.2 (36.7) | 0.069 |